Compare Davita Inc (DVA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs SYSCO Corporation — how do they compare? Davita Inc trades at $178.65 (market cap $11.38B), while SYSCO Corporation trades at $84.59 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 3.5× Davita Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SYY | |
|---|---|---|
Market Cap | $11.38B | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $91.16 |
52-Week Low | $103.87 | $69.30 |
Enterprise Value | $24.10B | $53.50B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
SYY trades at $83.87, down 0.5% for the day, with a neutral technical signal and bullish moving averages. The company reported Q4 2026 EPS of $1.53, beating estimates, and revenue of $81.37B in 2025, with steady growth. Analyst consensus is a Buy with a $88.25 price target, and recent news highlights strong quarterly results and efficiency initiatives.
Outlook is positive due to earnings beats and growth initiatives, but risks include margin pressure and debt levels. The stock offers value with a P/E of 23.02 and P/S of 0.48, supported by institutional optimism, though macroeconomic uncertainty remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
